SUVEN LIFE SCIENCES LTD (SUVEN) financials

SUVEN LIFE SCIENCES LTD (SUVEN) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.[1][2]

Market Cap: ₹8,061Cr.
Current Price: ₹285
ROE: -5.59%
ROCE: -5.53%
Book Value: ₹57.0
Dividend Yield: 0.00%
52W High / Low: ₹403/124

In Jun 2026, SUVEN LIFE SCIENCES LTD (SUVEN) reported sales ₹4 Cr and net profit ₹-16 Cr.

Annual TTM: sales ₹9 Cr, net profit ₹-56 Cr.

Shareholding: Promoters 65.47% (Jul 2026), FIIs 0.48% (Jul 2026), DIIs 2.73% (Jul 2026), Public 31.32% (Jul 2026), No. of Shareholders 66,647% (Jul 2026).

SUVEN quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	3	2	1	2	1	3	2	4
Expenses	16	15	16	16	19	18	18	25
Operating Profit	-14	-13	-15	-14	-18	-15	-16	-21
OPM %	-530%	-826%	-1,014%	-749%	-1,947%	-530%	-1,066%	-588%
Other Income	4	2	1	1	4	3	7	8
Interest	0	0	0	0	0	0	0	0
Depreciation	1	2	1	1	1	1	2	2
Profit before tax	-11	-13	-15	-15	-15	-13	-11	-16
Tax %	0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	-11	-13	-15	-15	-15	-13	-11	-16
EPS in Rs	-0.51	-0.61	-0.69	-0.68	-0.68	-0.59	-0.42	-0.61
Raw PDF	—	—	—	—	—	—	—	—

SUVEN profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	13	13	12	14	12	7	7	9
Expenses	48	44	48	41	43	58	70	79
Operating Profit	-35	-30	-36	-28	-31	-52	-63	-70
OPM %	-279%	-226%	-308%	-204%	-264%	-778%	-885%	-794%
Other Income	14	8	5	14	29	11	14	21
Interest	1	1	1	0	0	0	0	1
Depreciation	4	4	4	7	6	6	6	6
Profit before tax	-26	-28	-36	-20	-9	-47	-55	-56
Tax %	-47%	-19%	0%	0%	-11%	0%	0%	—
Net Profit	-14	-23	-36	-20	-8	-47	-55	-56
EPS in Rs	-0.72	-1.19	-1.66	-0.92	-0.37	-2.16	-2.08	-2.30
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	—

SUVEN balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	13	13	15	22	22	22	26
Reserves	389	375	389	461	832	824	778	1,477
Borrowings	3	6	5	3	2	1	0	17
Other Liabilities	35	16	9	7	5	5	9	11
Total Liabilities	439	410	415	486	860	851	809	1,531
Fixed Assets	22	25	21	38	37	28	60	73
CWIP	0	0	5	4	0	0	0	4
Investments	359	242	295	426	528	653	714	1,094
Other Assets	58	143	95	19	295	170	35	361
Total Assets	439	410	415	486	860	851	809	1,531

SUVEN cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-12	-45	-37	-37	-23	-21	-49	-68
Cash from Investing Activity	-4	42	2	-107	-349	-1	44	-686
Cash from Financing Activity	5	4	35	146	396	-1	-1	757
Net Cash Flow	-11	1	1	2	24	-22	-5	3
Free Cash Flow	-52	-48	-43	-56	-26	-18	-86	-73
CFO/OP	6%	120%	117%	99%	79%	87%	93%	109%

SUVEN shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Jul 2026
Promoters	70.26%	70.26%	70.26%	67.36%	67.36%	70.15%	70.08%	65.47%
FIIs	0.34%	0.25%	0.58%	1.17%	1.07%	0.91%	0.56%	0.48%
DIIs	1.05%	0.01%	0.03%	3.39%	3.39%	4.62%	2.93%	2.73%
Public	28.35%	29.47%	29.12%	28.07%	28.18%	24.32%	26.42%	31.32%
No. of Shareholders	63,537	64,603	66,159	64,921	64,381	63,915	66,791	66,647

SUVEN key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	3	66	48	40	22	40	73	78
Inventory Days	0	—	—	—	—	—	—	—
Days Payable	—	—	—	—	—	—	—	—
Cash Conversion Cycle	3	66	48	40	22	40	73	78
Working Capital Days	56	1,181	1,265	281	443	375	427	768
ROCE %	7%	-6%	-7%	-9%	-4%	-2%	-6%	-6%

SUVENUpdated 14 Oct 2026, 19:56

Suven Life Sciences Ltd

SUVENUpdated 14 Oct 2026, 19:56

Market Cap

₹8,061Cr.

Current Price

₹285

High / Low

₹403/124

ROE-5.59%

ROCE-5.53%

Book Value₹57.0

Face Value₹1.00

Dividend Yield0.00%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	4	11	6	2	-3	0	-3	-0.13
Sep 2023	3	11	13	2	3	0	3	0.13
Dec 2023	2	12	6	2	-5	0	-5	-0.22
Mar 2024	2	9	4	2	-4	-24	-3	-0.14
Jun 2024	1	11	4	1	-8	0	-8	-0.35
Sep 2024	3	16	4	1	-11	0	-11	-0.51
Dec 2024	2	15	2	2	-13	0	-13	-0.61
Mar 2025	1	16	1	1	-15	0	-15	-0.69
Jun 2025	2	16	1	1	-15	0	-15	-0.68
Sep 2025	1	19	4	1	-15	0	-15	-0.68
Dec 2025	3	18	3	1	-13	0	-13	-0.59
Mar 2026	2	18	7	2	-11	0	-11	-0.42
Jun 2026	4	25	8	2	-16	0	-16	-0.61

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	521	5	361	9	12	152	28	109	5.7
Mar 2016	499	6	369	19	18	126	20	100	5.24
Mar 2017	543	6	378	21	21	159	23	123	6.47
Mar 2018	625	5	392	23	21	230	31	158	8.3
Mar 2019	286	2	237	27	11	63	38	39	2.05
Mar 2020	13	1	48	14	4	-26	-47	-14	-0.72
Mar 2021	13	1	44	8	4	-28	-19	-23	-1.19
Mar 2022	12	1	48	5	4	-36	0	-36	-1.66
Mar 2023	14	0	41	14	7	-20	0	-20	-0.92
Mar 2024	12	0	43	29	6	-9	-11	-8	-0.37
Mar 2025	7	0	58	11	6	-47	0	-47	-2.16
Mar 2026	7	0	70	14	6	-55	0	-55	-2.08
TTM	9	1	79	21	6	-56	—	-56	-2.3

Shareholding pattern

As of Jul 2026%

Holder	Share
Promoters	65.47%
FIIs	0.48%
DIIs	2.73%
Public	31.32%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	69.56%	0.54%	0.01%	29.88%
Mar 2024	69.56%	0.46%	1.05%	28.91%
Jun 2024	70.26%	0.45%	1.05%	28.21%
Sep 2024	70.26%	0.33%	1.05%	28.34%
Dec 2024	70.26%	0.34%	1.05%	28.35%
Mar 2025	70.26%	0.25%	0.01%	29.47%
Jun 2025	70.26%	0.58%	0.03%	29.12%
Sep 2025	67.36%	1.17%	3.39%	28.07%
Dec 2025	67.36%	1.07%	3.39%	28.18%
Mar 2026	70.15%	0.91%	4.62%	24.32%
Jun 2026	70.08%	0.56%	2.93%	26.42%
Jul 2026	65.47%	0.48%	2.73%	31.32%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	13	547	109	105	773	172	107	0	494	773
Mar 2016	13	611	83	68	774	305	7	23	438	774
Mar 2017	13	719	71	74	876	306	10	366	195	876
Mar 2018	13	854	34	114	1014	308	25	381	301	1014
Mar 2019	13	389	3	35	439	22	0	359	58	439
Mar 2020	13	375	6	16	410	25	0	242	143	410
Mar 2021	13	389	5	9	415	21	5	295	95	415
Mar 2022	15	461	3	7	486	38	4	426	19	486
Mar 2023	22	832	2	5	860	37	0	528	295	860
Mar 2024	22	824	1	5	851	28	0	653	170	851
Mar 2025	22	778	0	9	809	60	0	714	35	809
Mar 2026	26	1477	17	11	1531	73	4	1094	361	1531

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	143	-110	179	212
Mar 2016	90	-62	-68	-40
Mar 2017	147	-353	-30	-236
Mar 2018	105	-38	-52	15
Mar 2019	-12	-4	5	-11
Mar 2020	-45	42	4	1
Mar 2021	-37	2	35	1
Mar 2022	-37	-107	146	2
Mar 2023	-23	-349	396	24
Mar 2024	-21	-1	-1	-22
Mar 2025	-49	44	-1	-5
Mar 2026	-68	-686	757	3

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	28	39	31	36	3	66	48	40	22	40	73	78
Inventory Days	165	183	222	329	0	—	—	—	—	—	—	—
Days Payable	89	78	91	134	—	—	—	—	—	—	—	—
Cash Conversion Cycle	105	144	162	231	3	66	48	40	22	40	73	78
Working Capital Days	49	60	45	85	56	1,181	1,265	281	443	375	427	768
ROCE %	31%	17%	19%	25%	7%	-6%	-7%	-9%	-4%	-2%	-6%	-6%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of SUVEN LIFE SCIENCES LTD (SUVEN)?

The reported market capitalisation for SUVEN LIFE SCIENCES LTD (SUVEN) is ₹8,061Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of SUVEN?

The current price shown for SUVEN LIFE SCIENCES LTD (SUVEN) on Fincrux is ₹285 with a 52-week high/low of ₹403/124.

What were SUVEN latest quarterly results?

For Jun 2026, SUVEN LIFE SCIENCES LTD (SUVEN) reported sales ₹4 Cr and net profit ₹-16 Cr (figures in ₹ crore unless noted).

What are SUVEN annual sales and net profit?

For TTM, SUVEN LIFE SCIENCES LTD (SUVEN) shows sales of ₹9 Cr and net profit of ₹-56 Cr on the Fincrux profit & loss statement.

Who owns SUVEN LIFE SCIENCES LTD (SUVEN)?

Latest shareholding for SUVEN LIFE SCIENCES LTD (SUVEN) on Fincrux: Promoters 65.47% (Jul 2026), FIIs 0.48% (Jul 2026), DIIs 2.73% (Jul 2026), Public 31.32% (Jul 2026), No. of Shareholders 66,647% (Jul 2026).

Where can I find SUVEN LIFE SCIENCES LTD (SUVEN) financials?

SUVEN LIFE SCIENCES LTD (SUVEN) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show SUVEN balance sheet and cash flow?

Yes. The SUVEN LIFE SCIENCES LTD (SUVEN) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 14 October 2026 at 19:56